Evidence map›Paper›PMID 32245990›Full record

ArticleScientific reports2020

Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus.

R Lande, R Palazzo, N Gestermann, C Jandus, M Falchi, F Spadaro, V Riccieri, E A James, A Butera, M Boirivant and 23 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. A Hairy Cituation - PADIs in Regeneration and Alopecia.Frontiers in cell and developmental biology · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 10 institutions in 3 countries.

R LandeIstituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.
R PalazzoIstituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.
N GestermannUniversity Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.
C JandusTranslational tumor immunology group, Department of fundamental oncology, University of Lausanne, 1066, Epalinges, Switzerland.
M FalchiIstituto Superiore di Sanità, National AIDS Center, 00166, Rome, Italy.
F SpadaroIstituto Superiore di Sanità, Confocal Microscopy Unit, Core Facilities, Rome, Italy.
V RiccieriDivision of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.
E A JamesDepartment of Translational Research, Benaroya Research Institute, Seattle, WA, USA.
A ButeraIstituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.
M BoirivantIstituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.
L FeldmeyerUniversity Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.
I SurbeckUniversity Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.
J Di LuccaUniversity Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.
F StuberUniversity Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.
F R SpinelliDivision of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.
E BottiDepartment of Systems Medicine University of Tor Vergata, Dermatology Unit, Rome, Italy.
B MarinariDepartment of Systems Medicine University of Tor Vergata, Dermatology Unit, Rome, Italy.
L BianchiDepartment of Systems Medicine University of Tor Vergata, Dermatology Unit, Rome, Italy.
R Pica"Sandro Pertini" Hospital, IBD, GE Unit, Rome, Italy.
B CerbelliDepartment of Radiological, oncological and anatomo-pathological sciences, Sapienza University, Rome, Italy.
K GiannakakisDepartment of Pathology, Sapienza University, Rome, Italy.
S E AuteriIstituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.
I DanielsAcademic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
L G DurrantAcademic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
S HorstmanDepartment of Translational Research, Benaroya Research Institute, Seattle, WA, USA.
A CostanzoSkin pathology laboratory, Dermatology Unit, IRCCS Humanitas clinical and research center, Rozzano, Milan, Italy.
P RomeroTranslational tumor immunology group, Department of fundamental oncology, University of Lausanne, 1066, Epalinges, Switzerland.
C AlessandriDivision of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.
F ContiDivision of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.
G ValesiniDivision of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.
M GillietUniversity Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.
C ChizzoliniDepartment of Immunology and Allergy, University Hospital and Medical School, Geneva, Switzerland.
L FrascaIstituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy. loredana.frasca@iss.it.
Sapienza University of Rome · ITIstituto Superiore di Sanità · ITUniversity Hospital of Lausanne · CHUniversity of Rome Tor Vergata · ITBenaroya Research InstituteUniversity Hospital of Geneva · CHUniversity of Lausanne · CHUniversity of Nottingham · GBHumanitas University · ITOspedale Sandro Pertini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LL37 exerts a dual pathogenic role in psoriasis. Bound to self-DNA/RNA, LL37 licenses autoreactivity by stimulating plasmacytoid dendritic cells-(pDCs)-Type I interferon (IFN-I) and acts as autoantigen for pathogenic Th17-cells. In systemic lupus erythematosus (SLE), LL37 also triggers IFN-I in pDCs and is target of pathogenic autoantibodies. However, whether LL37 activates T-cells in SLE and how the latter differ from psoriasis LL37-specific T-cells is unknown. Here we found that 45% SLE patients had circulating T-cells strongly responding to LL37, which correlate with anti-LL37 antibodies/disease activity. In contrast to psoriatic Th17-cells, these LL37-specific SLE T-cells displayed a T-follicular helper-(T

Indexed as

Antibodies, AntinuclearAntibody FormationAnti-Citrullinated Protein AntibodiesAntimicrobial Cationic PeptidesAutoantibodiesCathelicidinsDendritic CellsDNAFemaleHumansLupus Erythematosus, SystemicMalePsoriasisTh17 CellsT-LymphocytesAntibodies, AntinuclearAnti-Citrullinated Protein AntibodiesAntimicrobial Cationic PeptidesAutoantibodiesCathelicidinsDNA

Identifiers

PMID32245990
PMCPMC7125190
OpenAlexW3014263426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.